NIK SMI1 manufacturers
- NIK SMI1
-
- $75.00
-
2026-07-14
- CAS:1660114-31-7
- Purity: 99.48%
- Supply Ability: 10g
|
| | NIK SMI1 Basic information |
| Product Name: | NIK SMI1 | | Synonyms: | NIK SMI1;(R)-6-(3-((3-Hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-4-methoxypicolinamide;2-Pyridinecarboxamide, 6-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-3-pyrrolidinyl]ethynyl]phenyl]-4-methoxy-;NIK inhibitor 4f(NIK SMI1);NIK SMI1,Nuclear factor-κB,NIK SMI 1,Nuclear factor-kappaB,inhibit,Inhibitor,NF-κB,NIK SMI-1;4-methoxy-6-(3-methylphenyl)pyridine-2-carboxamide;NIK SMI1, 10 mM in DMSO | | CAS: | 1660114-31-7 | | MF: | C20H19N3O4 | | MW: | 365.38 | | EINECS: | | | Product Categories: | | | Mol File: | 1660114-31-7.mol |  |
| | NIK SMI1 Chemical Properties |
| Boiling point | 626.7±55.0 °C(Predicted) | | density | 1.39±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (273.69 mM) | | form | Solid | | pka | 11.14±0.20(Predicted) | | color | Off-white to pink | | InChI | 1S/C20H19N3O4/c1-23-9-8-20(26,19(23)25)7-6-13-4-3-5-14(10-13)16-11-15(27-2)12-17(22-16)18(21)24/h3-5,10-12,26H,8-9H2,1-2H3,(H2,21,24)/t20-/m0/s1 | | InChIKey | LQSHXYHWYGKAMX-FQEVSTJZSA-N | | SMILES | NC(C1=NC(C2=CC(C#C[C@]3(C(N(CC3)C)=O)O)=CC=C2)=CC(OC)=C1)=O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | NIK SMI1 Usage And Synthesis |
| Uses | NIK SMI1 is a highly potent and selective NF-κB-inducing kinase (NIK) inhibitor. | | Biological Activity | NIK SMI1 is an orally active, ATP site-targeting, potent and selective NF-KB-inducing kinase inhibitor (h/m NIK IC50 = 230/395 pM; hKHS1/hPKD1/hLRRK2 = 49.6/75.2/247.8 nM) th at selectively disrupts noncanonical NF-KB signaling (anti-LTβR-induced p52 nuclear translocation IC50 = 70 nM; TNFα-induced p65 RelA nuclear translocation IC50 >2 μM). SMI1 inhibits BAFF receptor- and CD40-mediated singling in cultures (human and murine B-cells) and shows in vivo efficacy in the NZB/W F1 murine experimental lupus model (6-400 mg/kg/day, b.i.d. p.o.). | | in vivo | C57BL/6 mice are treated twice daily for 7 days with orally administered NIK SMI1 or with three injections of recombinant BAFF receptor fusion protein (Br3- mIgG2a) over the course of the 7-day experiment as a positive control. The nonlinearity of exposure relative to dose between 100 and 200 mg/kg is a result of saturation of clearance mechanisms. The pharmacology of NIK SMI1 is examined in SD rat, CD-1 mouse, beagle, and cynomologous monkey with 20, 32, 18, and 7.8 mL/kg per min, respectively. Volume of distribution (Vd, L/kg) is 1.35, 1.58, 0.778, and 1.39, respectively[1]. |
| | NIK SMI1 Preparation Products And Raw materials |
|